Structural studies on mammalian integral membrane proteins have long been hampered by their instability in detergent. This is particularly true for the agonist conformation of G protein-coupled receptors (GPCRs), where it is thought that the movement of helices that occurs upon agonist binding results in a looser and less stable packing in the protein. Here, we show that mutagenesis coupled to a specific selection strategy can be used to stabilize the agonist and antagonist conformations of the adenosine A2a receptor. Of the 27 mutations identified that improve the thermostability of the agonist conformation, only three are also present in the 17 mutations identified that improve the thermostability of the antagonist conformation, suggesting that the selection strategies used were specific for each conformation. Combination of the stabilizing mutations for the antagonist-or agonist-binding conformations resulted in mutants that are more stable at higher temperatures than the wild-type receptor by 17°C and 9°C, respectively. The mutant receptors both showed markedly improved stability in short-chain alkyl-glucoside detergents compared with the wild-type receptor, which will facilitate their structural analysis.
G
protein-coupled receptors (GPCRs) represent one of the largest single families of integral membrane proteins in the human genome and bind multifarious ligands that mediate many physiological processes, which explains why GPCRs represent a major proportion of drug targets (1) . The binding of an extracellular ligand to a GPCR promotes coupling of the receptor to trimeric G proteins, situated on the intracellular side of the plasma membrane, triggering a signaling cascade. Despite sharing common features such as seven transmembrane helices and conserved signatures in their amino acid sequence (2), the sequence homology between different GPCRs is rather low. Detailed structure determination of GPCRs is therefore required to elucidate the mechanism of receptor activation to improve the design of both agonist and antagonist ligands of medical relevance.
For many years, crystallographic studies of GPCRs were limited to rhodopsin because of its abundance in native sources (retina) and its intrinsic stability in the dark state (3, 4) . However, even rhodopsin has been shown to be structurally more dynamic in detergent solution than in lipid bilayers (5) , and such flexibility is more pronounced for GPCRs that bind to diffusible ligands. Another obstacle to structural analysis, and especially to the formation of well ordered crystals, arises from the conformational heterogeneity of these receptors (6, 7) . The active agonist-bound state of GPCRs is normally found to be intrinsically less stable than the inactive antagonist-bound state, probably reflecting the receptor requirement for higher flexibility in its active state (8) . Agonist binding to the receptor triggers the recruitment of G ␣ protein binding to the intracellular side of the receptor, possibly via a succession of different conformations (7, 9, 10) .
Site-directed mutagenesis was used by Bowie and coworkers to improve the stability of two bacterial membrane proteins (11) (12) (13) . Rhodopsin has also been stabilized by 10°C, although in this case a disulfide bond was engineered between the N terminus and the third extracellular loop based on structural data (14) . Recently, we simultaneously improved both the thermostability and conformational homogeneity of a GPCR, the turkey ␤ 1 adrenergic receptor (␤ 1 AR). The stabilized GPCR mutant, ␤ 1 AR-m23, was preferentially in an antagonist-bound conformation, and its thermostability was 21°C higher than the wild-type receptor (15) , making it similar in stability to darkstate rhodopsin. In the present work, we further extended this approach of ''conformational thermostabilization'' on the human adenosine A 2a receptor (A 2a R) and carried out, in parallel, selection for two distinct conformations, the antagonist-and agonist-bound states.
Results
Alanine-Scanning Mutagenesis. Human A 2a R can be solubilized in the mild detergent dodecylmaltoside (DDM), and ligandbinding activity is retained at 4°C for many days, although it is much less stable after purification, probably because of the loss of bound lipids (16) . The apparent melting temperature (T m ) of wild-type human A 2a R solubilized in 2% DDM when assayed with either the agonist [
3 H]-5Ј-N-ethylcarboxamidoadenosine (NECA) or the antagonist [ 3 H]-ZM241385 is 23°C (data not shown); in this context, the apparent T m is defined as the temperature at which 50% of the binding activity remains after a 30-min incubation (15) . By comparison, in similar conditions, rhodopsin has an apparent T m of 55°C and turkey ␤ 1 AR, 32°C (15) . To make the T m determination for the wild-type A 2a R more reproducible under conditions of fluctuating laboratory temperature, we included 10% glycerol upon solubilization, which raised the apparent T m of the wild-type receptor from 23°C to 30°C.
The construct used in this study, M-A2aTr316-H10, expresses a maltose-binding protein-A 2a R fusion protein with a C-terminal 96-residue truncation designed to remove protease-sensitive sites, followed by a His 10 tag (16) . Each residue in A 2a R between Pro-2 and Ala-316 was individually mutated to Ala; if the wild-type residue was Ala, then the replacement was Leu. A total of 315 mutants were expressed in Escherichia coli and screened for activity in detergent solution before and after incubation at 30°C (Fig. 1) . Our goal was to find mutations that would enhance the thermal stability of the receptor preferentially in either an agonist-or antagonist-binding conformation, preferably without ligand bound, so that ligand-affinity purification could be used for the subsequent production of receptors for crystallization. The stability of the mutants, therefore, was tested by using in parallel both the agonist Fig. S1 (17, 18) ], which shifts the receptor equilibrium toward the R conformation. Despite the many complexities in this thermostability assay, we found this strategy for selecting thermostable mutants was indeed successful.
Levels of expression were estimated by ligand binding, using ligand concentrations 5-to 10-fold above K D to minimize the impact of possible changes in affinity. When the first round of mutants from the Ala scan was assayed, a mutant with improved stability (Ն65% or 70% of residual activity for antagonist or agonist selection, respectively) was accepted only if the expression of active receptor was no less than 30% (agonist selection) or 40% (antagonist selection) that of wild-type A 2a R (Fig. 1) ; there was no significant correlation between thermostability and improved expression. Using these cutoff values, we selected 27 stabilizing mutations by agonist and 17 by antagonist binding (Table S1 ). The stabilizing point mutations populate two distinct subsets, as defined by agonist or antagonist binding. Only three mutants were found to have a stabilizing effect for both conformations, i.e., G114A, G118A, and A203L ( Fig. 1 ). Thermostabilizing mutations appeared mainly to be residues that are predicted from the rhodopsin structure to be exposed either to the lipid or the aqueous environment (27 residues in total; Table  S1 ), although some (10 residues) appeared to be partially buried, and the remaining seven residues were predicted to be totally buried. Ten of the 27 mutations that stabilized the agonistbinding conformation were found either in the third intracellular loop or at the putative cytoplasmic end of helix 6 (Fig. 1C) .
Combining Mutations. Thermostabilizing mutations can be additive (11, 15) , so we assembled some of the best mutations identified in the initial screening into individual mutant receptors. The goal was to improve simultaneously the receptor stability in detergent solution and its conformational homogeneity in either an agonist or antagonist conformation. The second generation of mutants was therefore synthesized by combining stabilizing mutations for each specific conformation (Table S1 ). The combination of clusters of adjacent mutations (Table S1 , boxed) often resulted in receptor variants that were less thermostable than the single mutants, as was also found for turkey ␤ 1 AR (15) . From this second round of mutagenesis, the most thermostable combinations obtained were Rag1 (A184LϩR199AϩL272A) and Rant5 (A54LϩT88AϩV239A), as determined by agonist or antagonist binding, respectively. Compared with the wild-type receptor, Rag1 showed an increase in apparent T m of 5°C both in the unliganded and agonistoccupied state, whereas the T m of Rant5 was 11°C and 14°C higher than for the wild-type receptor for the unliganded and antagonist-occupied state, respectively. To explore the possibility of further stabilization, Rag1 and Rant5 were subjected to one-third round of mutagenesis. Of many combinations screened, we identified Rag23 (F79A, A184L, R199A, L208A, L272A) and Rant21 (A54L, T88A, K122A, V239A) as the most thermostable variants, with a 9°C and 17°C, respectively, increase in the apparent T m of the ligand-occupied state, compared with wild type (Fig. 2 and Table  S2 ). A list of the receptor variants generated in the second and third round of mutagenesis is given in Table S3 .
Saturation Curves and Competition Assays.
To characterize the conformational identity of the thermostable mutants, we carried out saturation-binding and competition assays using several agonist and antagonist ligands (Table S4 and Fig. 3 Fig. 3A and Table S4 , but it was included in the competition curves using agonists to displace antagonists (Table  1 and Fig. 3 E and F) . This may account for the weaker affinity values for NECA in the competition assay, compared with the saturation-binding assay. Affinity values of wild-type and mutant receptors for both ligands are summarized in Table 1 and Table  S4 , obtained from data plotted in Fig. 3 .
Combining stabilizing mutations for the agonist-binding con- Tables 1 and S4 .
formation led to receptor variants still capable of binding to both agonist and antagonist ligands (data not shown). Further combinations were therefore screened to make Rag23; the mutation F79A was included in Rag23, despite not being thermostabilizing, because the data from the original screen suggested it was preferentially in the agonist-binding conformation ( Fig. 1 A and  B) . Further work subsequently showed that these binding data arose because of F79A being less sensitive to the allosteric antagonism of Na ϩ (results not shown). The inclusion of F79A mutation fits with our goal, because Rag23, when compared with the parental mutant Rag1, showed both enhanced thermostability (an additional 4°C in the ligand-occupied state; Table S2 ) and 5-fold reduced affinity for the antagonist [ 3 H]-ZM241385 compared with the wild type (Table S4) .
Increased Thermostability Correlates with Independence from Lipids.
Purification of the wild-type A 2a R required the inclusion of cholesteryl hemisuccinate (CHS) and glycerol to maintain its ligand-binding activity (16) . From our observations, we found that CHS increases the size of the detergent-lipid micelle around a membrane protein, and we hypothesize that the major stabilization effect of CHS is due to the retention of lipids around the protein. This is equivalent to adding additional lipids to the detergent during purification, which also has a stabilizing effect (19) (20) (21) . We therefore probed the stability of some of the Rant mutants by varying the concentration of DDM or lipids at a fixed concentration of receptor. The enhanced stability of receptor variants was measurable not only by an increased survival in DDM solution (Fig. 4A ) but also by a reduced requirement for lipids during purification (Fig. 4B) . We then tested whether the increase in receptor thermostability had widened the detergent range we could use for purification and subsequently crystallization ( Table 2) . Solubilization of the receptor was carried out with 1% DDM, and detergent exchange was performed after immobilization of the receptor via its His 10 tag to Ni 2ϩ -affinity resin. In general, there was a direct correlation between receptor stability and the alkyl chain length of detergents (Table 2) . Surprisingly, the antagonist-binding conformation of the wild-type receptor was less stable in shorter chained maltoside detergents than the agonist-binding state yet another reflection of the structural differences between the two states. Thus, the increased stability of the A 2a R mutants has removed the requirement of additional lipids during purification to maintain the activity of the receptor and will allow a larger range of detergents to be used during crystallization.
Discussion
GPCRs represent a challenge for structural studies, because they are often rapidly inactivated upon solubilization in detergent, and also because each receptor exists in at least two, and possibly multiple, conformational states (6) . In addition, the agonistbound state of GPCRs is frequently found to be less stable than the antagonist-bound state (8) making it even more difficult to crystallize. The two GPCR structures so far determined by x-ray crystallography represent conformations close to the antagonistbound state, and both of these proteins, rhodopsin and the human ␤2 adrenergic receptor (4, 22, 23) , are among the most stable GPCRs. In contrast, A 2A R is rapidly inactivated when purified in DDM unless stabilizing agents such as cholesteryl hemisuccinate are present throughout (16) .
In this study, we have used the technique of conformational thermostabilization (15) to generate two variants of the human A 2a R that correspond to the agonist-and antagonist-binding (Rant 21 mutant) . Values are representative of two independent experiments. Each data point was assayed in triplicate and plotted as mean Ϯ SD (SD is not shown when is Ͻ 1% of the mean value). Solubilization of receptors and detergent exchange was performed during the IMAC step as described in Fig. 3 . SD is Ͻ1°C. *No detectable binding of the radioligand.
conformations. The initial alanine scan identified 17 thermostabilizing mutations for the antagonist-and 27 for the agonistbinding conformation, and the two patterns were largely nonoverlapping (Fig. 1) , suggesting that the different mutations stabilize two different states of the receptor. In a second round of mutagenesis, combinations of single thermostable mutants were combined, tested for expression levels and thermostability, and then further refined in a third round. For the generation of an A 2A R mutant in the antagonist conformation, this process progressed linearly, with the contribution of single mutations usually being additive and simultaneously increasing the thermostability of both the unliganded and antagonist-bound conformations. This process resulted in the mutant Rant21, which is more stable in both the unliganded and antagonist-occupied states by 10°C and 17°C, respectively, relative to the wild type ( Table S2) . Generation of the A 2a R mutant in the agonistbinding conformation was less straightforward; for example, a single mutation might increase the thermostability of the agonist-occupied state, but not necessarily the stability of the unliganded R* state. It is possible that different mutations affected differentially multiple states of the receptor within the agonist-binding population (7), which resulted in the difficulty of assembling multiple mutations into a single highly stable receptor in an agonist conformation (further work, in progress, is still required to improve the selection procedure of specific agonist binding states). The best agonist-binding mutant obtained so far was Rag23, which displayed a thermostability increase of 9°C in its agonist-occupied state, but it is more stable than the wild type by only 1°C in the unliganded state (Table S2 ). This represents a substantial 27-fold increase in thermostability of the agonistoccupied state and a significant improvement in stability in short-chain detergents ( Table 2) .
The pharmacological profile of Rant21 showed that the mutant receptor bound the antagonists ZM241385, XAC, and theophylline with similar affinities compared with the wild-type receptor. In contrast, binding to agonists was dramatically reduced, with the affinity for R-PIA and [ 3 H]-NECA being weakened by at least a factor of 225-and 14-fold, respectively (Table 1 and Table S4 ). This could suggest that the mutations in Rant21 have a global effect on the receptor structure, so that it preferentially adopts an antagonist-bound conformation. An alternative explanation is that the mutations are all in the ligand-binding pocket, and that coincidentally they specifically inhibit agonist binding, leaving antagonist binding unaffected (see also next paragraph). Mapping the mutations to the recently solved structure of the ␤ 2 adrenergic receptor (refs. 22 and 23 and Fig. S2) shows that K122 and A54 are both predicted to point into the lipid bilayer, V239 is at the interface between helices, and T88 is predicted to be in the ligand-binding pocket (24) . It is conceivable that at least part of the weakening of agonist binding could be due to a direct reduction in the agonist affinity through removal of either hydrogen bond(s) or hydrophobic contacts. The structure of Rant21 with antagonist bound would thus be extremely informative regarding the inactive state of the receptor, as has been found in the case of the rhodopsin and ␤ 2 AR structures. However, none of these structures is particularly illuminating about the agonist-bound state, because of the receptor conformational change that is predicted to occur upon agonist binding; this will necessitate the structure determination of receptors stabilized specifically in this activated state.
The mutant Rag23 contains five mutations that increase the thermostability of the A 2a R only when agonist is bound. Saturation-binding curves for the agonist [ 3 H]-NECA show that Rag23 binds it with marginally stronger affinity than the wildtype receptor; in contrast, binding of the antagonist [ 3 H]-ZM214385 was 5-fold weaker than wild type (Table S4 ). The positions of these mutations include two predicted to point into the lipid bilayer (F79A and L272A), with another two predicted to be at the interface between transmembrane helices (A184L and R199A), whereas the mutation at L208 is predicted to be in the connecting loop between helices 5 and 6 (inner loop 3; Fig.  S2 ). It is therefore likely that stabilization of the A 2a R in the agonist-bound conformation is due primarily to a global shift in structure as opposed to side chain-ligand interactions. We found it much more difficult to assemble the individual mutations that thermostabilize the agonist conformation compared with the combination of mutations to make the antagonist-stabilized Rant21. This may be partly due to the presence of multiple agonist conformations that differ in the degree of conformational change, such as has been proposed for the different effects of partial and full agonists (25) . In addition, the proposed conformational change, which is thought to be predominantly an outward movement of helix 6 (26) , may result in a more open structure that is more difficult to stabilize than the compact antagonist-bound conformation. The modest increase in stability of Rag23 compared with wild-type A 2a R relative to the stabilization of the antagonist conformations of both A 2a R and ␤ 1 AR (15) is probably a reflection of both these factors.
The A 2a R is now the second receptor that we have thermostabilized by alanine-scanning mutagenesis, so we were naturally very interested to examine whether there was any correlation in the residues the procedure selected. A comparison of the thermostabilizing mutations for the ␤ 1 AR (15) and for the antagonist conformation of A 2a R shows that there is little commonality between their positions in an alignment of the receptors. It may be that this is merely a reflection of their lack of homology, because they are only 23% identical, despite the expectation that the packing of the transmembrane ␣-helices would be very similar. In contrast, there is thought to be a substantial change in the orientation of at least helix 6 when agonists bind to GPCRs, so it is perhaps not surprising that there were only 3-aa residues that were identified as stabilizing the receptor in both the agonist and antagonist conformations, of 27 and 17 stabilizing mutations, respectively.
The properties of the two thermostabilized A 2a R mutants, Rant21 and Rag23, make them attractive for crystallization. Both mutants show a wider range of stability in the short-chain detergents that are preferred for crystallization than the wildtype receptor. Further experiments showed two important changes conferred on mutated receptors by thermostabilization. First, the mutant is significantly less sensitive to elevated detergent concentrations, and second, there is no longer a dependence upon the presence of lipids during purification to maintain ligand-binding activity. The removal of this lipid dependence now allows the preparation of Rant21 in small well defined detergent micelles that should facilitate the formation of well ordered crystals.
Materials and Methods
Materials. The construct M-A2aTr316-H10 in the E. coli expression vector pRG/III-hs-MBP used for site directed-mutagenesis was kindly provided by Markus Weiss (Novartis) and is described in ref. 16 . NECA was supplied by Amersham Biosciences and [ 3 H]-ZM241385 by American Radiolabeled Chemicals. X AC, R-PIA, NECA, and theophylline were purchased from Sigma. ZM241385 was from Tocris. Ni-nitrilotriacetic acid (Ni-NTA) agarose was obtained from Qiagen and Sephadex G-25 medium from Amersham Biosciences. All detergents were from Anatrace.
Mutagenesis. Mutants were generated by PCR using the QuikChange II methodology (Stratagene) and the expression plasmid as template. PCRs were transformed into DH5␣ ultracompetent cells prepared according to the Inoue method (27) , and individual clones were fully sequenced to check that only the desired mutation was present. Different mutations were combined by PCR as above by (i) designing pairs of oligonucleotides to include two to four multiple mutations (Table S1 , residues boxed in bold) or (ii) randomly, by including in the same PCR mix all of the pairs of primers that introduced the desired
